In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on Nephros (NEPH), with a price target of $16.00. The company’s shares closed last Tuesday at $8.17.
According to TipRanks.com, Vendetti is a 5-star analyst with an average return of 20.9% and a 51.7% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Applied DNA Sciences, Milestone Scientific, and Ra Medical Systems.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nephros with a $14.25 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.00 and a one-year low of $5.08. Currently, Nephros has an average volume of 17.86K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Renal Products segment comprises of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.
